Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT03748186

NCT03748186
Completed Phase 1

Who may be able to join

Who might be able to join this trial:

  • You are 18 years of age or older
  • Your cancer can be measured on a scan (confirm with trial site)
  • You are fairly active and able to care for yourself, with only mild limitations on daily activities (confirm with trial site)
  • Doctors expect you to live for more than 3 months
  • Your cancer has been confirmed by a pathology report or similar medical record
  • For Groups A and C: You have been diagnosed with a specific type of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that is high-grade serous (confirm with trial site)
  • For Group B: You have been diagnosed with a specific type of uterine (endometrial) cancer confirmed by a tissue test (confirm with trial site)
  • Your cancer has come back or continued to grow after previous treatment, and you have received between 1 and 3 prior treatment regimens, depending on your cancer type and treatment history (confirm with trial site)
  • You are able to provide a tissue sample from your tumor, either recently taken or stored from a previous biopsy

Who may not be able to join:

  • You have a low-grade (grade 1) ovarian cancer, or a clear cell, mucinous, or sarcomatous type of ovarian cancer (Group A)
  • You have a type of uterine cancer called carcinosarcoma, leiomyosarcoma, or stromal sarcoma (Group B)
  • You have previously been treated with a therapy that specifically targets a protein called FolRα, including certain antibody-drug combinations or vaccines
  • Your cancer did not respond to platinum-based chemotherapy during your very first course of treatment (Groups A and C)
  • You have received more than 3 prior cancer treatment regimens
  • You have had a severe or life-threatening allergic reaction to a type of drug called a monoclonal antibody or a related treatment
  • You have a serious pre-existing eye condition, severe lung disease (such as COPD or asthma), significant heart or blood vessel disease, or another serious uncontrolled medical condition
  • Your cancer has spread to the brain or the lining around the brain or spinal cord
  • You are currently taking part in another clinical trial that involves active treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 1
Sponsor
Sutro Biopharma, Inc.
Registry
clinicaltrials_gov
Start date
1 February 2019
Est. completion
4 June 2024

Where this trial is recruiting

🇪🇸 Spain 🇺🇸 United States

Primary endpoints

Part 1: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-002); Part 1: Define the recommended phase 2 dose (RP2D) of STRO-002; Part 1: Define the maximum tolerated dose (MTD) of STRO-002; Part 2: Evaluate preliminary anti-tumor activity (ovarian, Fallopian and primary peritoneal cancer patients); Part 2: Evaluate preliminary anti-tumor activity (endometrial cancer patients)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov